Artelo Biosciences, Inc. has announced a one-for-three reverse stock split of its common stock, effective March 10, 2026. This decision was made to reduce the number of outstanding shares from approximately 2,124,772 to about 708,323. The authorized shares of common stock will also be reduced from 500 million to 166,666,667, while the authorized shares of preferred stock will decrease from 69,444 to 23,148. The par value of the common stock remains unchanged at $0.001 per share. This move is aimed at improving the company's stock price and overall market perception, although it may not significantly alter the company's financial position. The company will republish certain financial information to reflect the changes in total par value due to the reverse split. The audited financial statements for the fiscal years ended December 31, 2024, and 2025, will be included in the filing. The reverse split is seen as a strategic move to enhance the company's marketability and attract potential investors, although it may also raise concerns about liquidity and shareholder dilution.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.